WEKO3
アイテム
{"_buckets": {"deposit": "051e984c-00d3-4bef-b8c2-ce87f97bd6db"}, "_deposit": {"created_by": 2, "id": "5926", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5926"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005926", "sets": ["30"]}, "author_link": ["25646", "25642", "25644", "25645", "25647", "25643"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-01-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "91", "bibliographicPageStart": "84", "bibliographicVolumeNumber": "75", "bibliographic_titles": [{"bibliographic_title": "The Prostate"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "BACKGROUND. Neoadjuvant hormonal therapy (NHT) is performed to improve the outcome in organ-confined prostate cancer. However, there is little information regarding the relationship between angiogenesis and NHT. The aim of this study was to identify a suitable method to evaluate the angiogenic status of tissue, and to determine the prognostic value of this method for biochemical recurrence in patients who had undergone radical prostatectomy after NHT.\nMETHODS. We analyzed 108 formalin-fixed specimens from patients treated by radical prostatectomy. NHT was administered in 48 patients (52.9%) and 60 patients who had a similar Gleason score and pT stage were selected as a non-NHT treated control group. Microvessel density (MVD) was measured using anti-CD31, anti-CD34, and anti-CD105 antibodies. The expressions of vascular endothelial growth factor (VEGF)-A and thrombospondin (TSP)-1 were also evaluated by immunohistochemistry. The prognostic value of CD31-, CD34-, and CD105-MVD for biochemical recurrence was investigated.\nRESULTS. The mean/SD of CD105-MVD in the NHT group (13.3/4.7) was significantly (P\u003c0.001) lower than that in the non-NHT group (125.8/7.3). In the NHT group, CD105-MVD was associated with pT stage and it was positively correlated with VEGF-A expression (r=0.56, P\u003c0.001) and negatively correlated with TSP-1 expression (r=0.42, P=0.003). CD105-MVD was identified as a significant predictor of biochemical recurrence (BCR) in patients treated with NHT (log rank test, P\u003c0.001). Although CD31- and CD34-MVD were significantly associated with pT stage or Gleason score in non-NHT group, they were not associated with pathological features and BCR in NHT group.\nCONCLUSIONS. Our results indicate that CD105-MVD reflects the angiogenic conditions in prostate cancer tissues treated with NHT. CD105-MVD was also identified as a significant and independent predictor of biochemical recurrence in prostate cancer patients who underwent radical prostatectomy with NHT.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "The Prostate, 75(1), pp.84-91; 2015", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley-Liss Inc."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1002/pros.22894", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2014 The Authors. The Prostate published by Wiley Periodicals, Inc."}, {"subitem_rights": "This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "02704137", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Miyata, Yasuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "25642", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mitsunari, Kensuke"}], "nameIdentifiers": [{"nameIdentifier": "25643", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Asai, Akihiro"}], "nameIdentifiers": [{"nameIdentifier": "25644", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takehara, Kosuke"}], "nameIdentifiers": [{"nameIdentifier": "25645", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mochizuki, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "25646", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakai, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "25647", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Pros75_84.pdf", "filesize": [{"value": "1.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1000000.0, "url": {"label": "Pros75_84.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5926/files/Pros75_84.pdf"}, "version_id": "ff39083f-c8c4-45d9-bf79-f8d07b36f74d"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Angiogenesis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Biochemical recurrence", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Neoadjuvant therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Thrombospondin-1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Vascular endothelial growth factor-A", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/35018", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-01-20"}, "publish_date": "2015-01-20", "publish_status": "0", "recid": "5926", "relation": {}, "relation_version_is_last": true, "title": ["Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy"], "weko_shared_id": -1}
Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy
http://hdl.handle.net/10069/35018
http://hdl.handle.net/10069/35018a964bf08-5830-4e0d-9fc2-9e1e4a4c595f
名前 / ファイル | ライセンス | アクション |
---|---|---|
Pros75_84.pdf (1.0 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-01-20 | |||||
タイトル | ||||||
タイトル | Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Angiogenesis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Biochemical recurrence | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Neoadjuvant therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Thrombospondin-1 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Vascular endothelial growth factor-A | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Miyata, Yasuyoshi
× Miyata, Yasuyoshi× Mitsunari, Kensuke× Asai, Akihiro× Takehara, Kosuke× Mochizuki, Yasushi× Sakai, Hideki |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | BACKGROUND. Neoadjuvant hormonal therapy (NHT) is performed to improve the outcome in organ-confined prostate cancer. However, there is little information regarding the relationship between angiogenesis and NHT. The aim of this study was to identify a suitable method to evaluate the angiogenic status of tissue, and to determine the prognostic value of this method for biochemical recurrence in patients who had undergone radical prostatectomy after NHT. METHODS. We analyzed 108 formalin-fixed specimens from patients treated by radical prostatectomy. NHT was administered in 48 patients (52.9%) and 60 patients who had a similar Gleason score and pT stage were selected as a non-NHT treated control group. Microvessel density (MVD) was measured using anti-CD31, anti-CD34, and anti-CD105 antibodies. The expressions of vascular endothelial growth factor (VEGF)-A and thrombospondin (TSP)-1 were also evaluated by immunohistochemistry. The prognostic value of CD31-, CD34-, and CD105-MVD for biochemical recurrence was investigated. RESULTS. The mean/SD of CD105-MVD in the NHT group (13.3/4.7) was significantly (P<0.001) lower than that in the non-NHT group (125.8/7.3). In the NHT group, CD105-MVD was associated with pT stage and it was positively correlated with VEGF-A expression (r=0.56, P<0.001) and negatively correlated with TSP-1 expression (r=0.42, P=0.003). CD105-MVD was identified as a significant predictor of biochemical recurrence (BCR) in patients treated with NHT (log rank test, P<0.001). Although CD31- and CD34-MVD were significantly associated with pT stage or Gleason score in non-NHT group, they were not associated with pathological features and BCR in NHT group. CONCLUSIONS. Our results indicate that CD105-MVD reflects the angiogenic conditions in prostate cancer tissues treated with NHT. CD105-MVD was also identified as a significant and independent predictor of biochemical recurrence in prostate cancer patients who underwent radical prostatectomy with NHT. |
|||||
書誌情報 |
The Prostate 巻 75, 号 1, p. 84-91, 発行日 2015-01-01 |
|||||
出版者 | ||||||
出版者 | Wiley-Liss Inc. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 02704137 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1002/pros.22894 | |||||
権利 | ||||||
権利情報 | c 2014 The Authors. The Prostate published by Wiley Periodicals, Inc. | |||||
権利 | ||||||
権利情報 | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | The Prostate, 75(1), pp.84-91; 2015 |